Neuronetics Q1 Revenue Rises 8%, Beats Estimates; Net Loss Narrows
Summary
Neuronetics reported Q1 revenue of $34.45 million, an 8% year-over-year increase, slightly exceeding analyst estimates. The company also narrowed its net loss per share to $0.16 from $0.21 a year ago and achieved a 6% reduction in operating expenses. While gross margin declined to 46.9% due to product mix, the company maintained its full-year 2026 revenue guidance of $160 million to $166 million. This report provides a positive update on the company's financial performance and operational efficiency, which is material for traders given the company's market capitalization and prior history of losses.
At the time of this announcement, STIM was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $140.6M. The 52-week trading range was $0.80 to $4.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.